LEADER 03067nam  2200625 a 450 
001 9910814853603321
005 20240417005910.0
010   $a0-309-21932-9
010   $a1-283-31196-8
010   $a9786613311962
010   $a0-309-21930-2
035   $a(CKB)2550000000058076
035   $a(OCoLC)769188485
035   $a(CaPaEBR)ebrary10506513
035   $a(SSID)ssj0000630697
035   $a(PQKBManifestationID)11390391
035   $a(PQKBTitleCode)TC0000630697
035   $a(PQKBWorkID)10747025
035   $a(PQKB)11528330
035   $a(MiAaPQ)EBC3378890
035   $a(Au-PeEL)EBL3378890
035   $a(CaPaEBR)ebr10506513
035   $a(CaONFJC)MIL331196
035   $a(OCoLC)923284553
035   $a(EXLCZ)992550000000058076
100   $a20121114d2011      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aPublic engagement and clinical trials $enew models and disruptive technologies : workshop summary /$fVictoria Weisfeld, Rebecca A. English, and Anne B. Clairborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation Board on Health Sciences Policy, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$d2011
215   $a1 online resource (115 p.)
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-309-21929-9 
320   $aIncludes bibliographical references.
327   $aIntroduction -- Recruitment challenges in clinical trials for different diseases and conditions -- Models for public engagement -- Messages and methods for public engagement -- The media -- Novel clinical trials designs -- The health system's structure and culture -- Toward a patient-centered strategy for clinical trials.
330   $aClinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.
606   $aClinical trials
615  0$aClinical trials.
676   $a610.72/4
701   $aWeisfeld$b Victoria$01602350
701   $aEnglish$b Rebecca A$01602351
701   $aClaiborne$b Anne B$01601264
712 02$aInstitute of Medicine (U.S.)
712 12$aPublic Engagement and Clinical Trials: New Models and Disruptive Technologies
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910814853603321
996   $aPublic engagement and clinical trials$93926301
997   $aUNINA